SITUATION REPORT: 15 JULY 2026
Another senior researcher just walked out of OpenAI’s door. This one is heading for the pharmacy.
Miles Wang, an OpenAI researcher focused on using AI to accelerate scientific and biological discovery, is leaving the company to launch his own startup built around AI models for drug discovery, according to TechCrunch AI, which cites four people with knowledge of his plans. Several other OpenAI researchers are expected to follow him out.
The numbers reported are serious. Wang is in talks to raise roughly $200 million at a $2 billion valuation, per two of TechCrunch’s sources. Lightspeed is in discussions to lead the round.
One caveat before we go further: Wang disputed the funding figures and the description of the company, but he didn’t offer corrected numbers or details. Lightspeed didn’t respond to a request for comment. Talks are ongoing and the deal isn’t final.
Tactical Points
- The startup has no product yet, and it already has a $2B price tag. That’s not a valuation of what exists. It’s a valuation of who’s building it and what they know.
- The strategy is drug repurposing, not drug invention. According to TechCrunch AI, Wang’s company may be working on AI models that find new uses for existing drugs, including ones that already failed in trials. This is the smart play. FDA-approved medicines have cleared safety testing already, which means a dramatically faster path to revenue than starting from a blank molecule.
- The founder is a Harvard dropout who joined OpenAI in 2024. He was working on a computer science bachelor’s degree and left it behind. At OpenAI he co-authored research on how AI models can automate and accelerate scientific discovery. That’s roughly two years from undergrad to a nine-figure raise.
- This is not an isolated event. It’s a pattern.
The Bigger Picture: AI Bio Is Getting Crowded Fast
Look at the last few months, as laid out by TechCrunch AI:
- Chai Discovery raised $400 million at a $3.8 billion valuation this week. It builds AI models that predict molecular interactions to identify new drugs. Co-founder Josh Meier also came out of OpenAI.
- Isomorphic Labs, the Google DeepMind spinout, pulled a $2.1 billion Series B in May.
- Wang’s startup now targets $200 million at $2 billion.
Three companies. Billions in capital. All chasing the same thesis: that frontier AI models are the fastest route to new medicine.
What stands out here is the talent flow. OpenAI has become the training ground for AI-bio founders. Meier passed through. Wang is leaving now, with colleagues in tow. The lab that built ChatGPT is quietly seeding an entire vertical.
Why This Matters
The status quo in pharma has been brutal for decades. Drug development costs billions per approved medicine, takes ten-plus years, and most candidates die in trials. That failure graveyard is exactly what Wang appears to be mining.
Here’s the insight worth holding onto: every failed trial produced data. Every shelved compound has known safety properties. If your AI can spot that a drug developed for one disease actually works on another, you skip years of safety testing and go almost straight to efficacy trials. Faster approval. Faster revenue. Lower risk.
That’s why investors are writing these checks before a product exists.
What To Watch
- Whether the round closes at reported terms. Wang pushed back on the figures. If the real number lands lower, that says something about how much of this is momentum versus substance.
- Who else leaves OpenAI. Several researchers are expected to join. Watch the names. They tell you what capability the startup is actually betting on.
- The first repurposing claim. Whoever publishes a validated AI-found new use for an approved drug first sets the benchmark for the whole category.
- Whether Big Pharma buys or builds. With three well-funded AI-bio players now on the board, the incumbents have a decision to make.
The AI-for-science narrative just stopped being a research paper topic and became a funding category. Expect more OpenAI departures, more billion-dollar seed-stage valuations, and a lot of pressure to show that any of this actually produces a medicine.
Full details on Wang’s plans and the funding talks are at the original TechCrunch AI report.